Although a wealth of knowledge is available on how best to reduce the burden of stroke and infectious neurological diseases, intervention and reduction of the burden of other non-communicable neurological disorders is much more complex and requires the development of new and more effective treatments and prevention measures. This book addresses this demand by collecting key elements required in developing novel treatments for non-communicable neurological disorders. Key chapters include the blood-brain barrier's important role in the treatment of neurological disorders, physiological barriers for drug delivery to brain, novel drug delivery systems and industrial production and regulatory aspects. Key FeaturesSummarizes key in vitro and in vivo evaluations that should be considered in developing successful brain drug delivery systems. Addresses points that should be considered, when large scales of brain drug delivery systems are produced at the industrial level, and how batch consistencies can be met. Helps formulation scientists to consider important regulatory requirements when developing novel drug delivery systems to brain. Includes an important chapter describing in vivo evaluation of diffusing therapeutic agents from the blood into the brain parenchyma and how this approach would complement the current imaging techniques such IVIS. Provides key information about the use of monoclonal antibodies for the treatment of neurological disorders.
